• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Thermo Fisher Scientific Elects New Director to Board

    2/19/25 4:00:00 PM ET
    $CVS
    $TMO
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Industrial Machinery/Components
    Industrials
    Get the next $CVS alert in real time by email

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Karen S. Lynch has been elected to its board of directors, effective February 19, 2025. The appointment brings the total number of Thermo Fisher board members to 12.

    Ms. Lynch is a seasoned health care executive with over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE:CVS), a leading health solutions company, she was responsible for leading more than 300,000 employees. Under Ms. Lynch's leadership, CVS Health touched the lives of more than 120 million consumers through its health care benefits and pharmacy benefits management businesses, and presence in over 9,000 community health destinations across the U.S. Prior to her service as president and CEO of CVS Health, Ms. Lynch served as an Executive Vice President of CVS Health and President of Aetna, and prior to that, Ms. Lynch held a number of executive positions at Aetna Inc., a health insurance company, Magellan Health Services, a health care management company, and at Cigna Corporation, a global health insurance company. Ms. Lynch began her career as a Certified Public Accountant at the auditing firm Ernst & Young LLP, and has previously served as a board member of CVS Health and U.S. Bancorp.

    "We are extremely pleased to have Karen join the board," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Her knowledge and insight will be an incredible asset as we continue to scale our company and deliver for our stakeholders."

    About Thermo Fisher Scientific

    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250219315440/en/

    Media Contact Information:

    Sandy Pound

    Phone: 781-622-1223

    E-mail: [email protected]

    Investor Contact Information:

    Rafael Tejada

    Phone: 781-622-1356

    E-mail: [email protected]

    Get the next $CVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS
    $TMO

    CompanyDatePrice TargetRatingAnalyst
    Thermo Fisher Scientific Inc
    $TMO
    12/11/2025$660.00Neutral → Buy
    Citigroup
    Thermo Fisher Scientific Inc
    $TMO
    12/9/2025$685.00Buy
    Goldman
    Thermo Fisher Scientific Inc
    $TMO
    12/8/2025$750.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Thermo Fisher Scientific Inc
    $TMO
    12/2/2025$670.00Overweight
    Morgan Stanley
    Thermo Fisher Scientific Inc
    $TMO
    12/1/2025$670.00Hold → Buy
    HSBC Securities
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    Thermo Fisher Scientific Inc
    $TMO
    9/11/2025$550.00Equal Weight → Overweight
    Barclays
    Thermo Fisher Scientific Inc
    $TMO
    8/19/2025Outperform
    William Blair
    More analyst ratings

    $CVS
    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Pettiti Gianluca sold $216,480 worth of shares (400 units at $541.20), decreasing direct ownership by 2% to 20,752 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/11/26 4:26:42 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Group President Shah Prem S covered exercise/tax liability with 247 shares, decreasing direct ownership by 0.40% to 61,509 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/5/26 6:23:10 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Thermo Fisher upgraded by Citigroup with a new price target

    Citigroup upgraded Thermo Fisher from Neutral to Buy and set a new price target of $660.00

    12/11/25 8:46:38 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Goldman initiated coverage on Thermo Fisher with a new price target

    Goldman initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $685.00

    12/9/25 8:54:23 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Thermo Fisher from Sector Weight to Overweight and set a new price target of $750.00

    12/8/25 8:17:51 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $CVS
    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Pharmacy Partners with U.S. Soccer Federation and National Women's Soccer League to Promote Community Health and Wellness

    Building on its relationship with the Washington Spirit, CVS expands its commitment to soccer through a new multi-year sponsorship with the league and federation, which includes a national community field investment and partnering with the Kansas City Current and Seattle Reign FCWOONSOCKET, R.I., Feb. 19, 2026 /PRNewswire/ -- CVS Pharmacy® has furthered its commitment to improving community health by becoming an Official Health and Wellness Partner of the U.S. Soccer Federation (USSF) and the National Women's Soccer League (NWSL) and is backing that sponsorship with a multi-year investment to develop community multi‑use soccer fields in select markets across the country.

    2/19/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Announces $5 Million Scholarship Program to Support Future Pharmacists in Louisiana

    Investment aims to strengthen the pharmacy workforce and expand access to care across the stateBATON ROUGE, La., Feb. 18, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced the launch of a new $5 million scholarship program designed to support aspiring pharmacists in the state of Louisiana. The initiative will provide financial assistance to students pursuing their Doctor of Pharmacy (PharmD) degree at either Xavier University of Louisiana or the University of Louisiana at Monroe. This initiative is part of CVS Health's broader commitment to advancing health equity, exp

    2/18/26 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Highlights Total revenues increased to $105.7 billion, up 8.2% compared to prior yearGAAP diluted EPS of $2.30 and Adjusted EPS of $1.09Full-Year Highlights Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior yearGAAP diluted EPS of $1.39 and Adjusted EPS of $6.75Generated cash flow from operations of $10.6 billionOperational Highlights CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations wi

    2/10/26 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $TMO
    SEC Filings

    View All

    SEC Form 13F-HR filed by CVS Health Corporation

    13F-HR - CVS HEALTH Corp (0000064803) (Filer)

    2/13/26 4:07:56 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Thermo Fisher Scientific Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    2/12/26 4:19:10 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 424B5 filed by Thermo Fisher Scientific Inc

    424B5 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    2/10/26 5:02:01 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $CVS
    $TMO
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $TMO
    Financials

    Live finance-specific insights

    View All

    CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Highlights Total revenues increased to $105.7 billion, up 8.2% compared to prior yearGAAP diluted EPS of $2.30 and Adjusted EPS of $1.09Full-Year Highlights Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior yearGAAP diluted EPS of $1.39 and Adjusted EPS of $6.75Generated cash flow from operations of $10.6 billionOperational Highlights CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses.Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations wi

    2/10/26 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Fourth quarter revenue grew 7% to $12.21 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. Fourth quarter adjusted EPS grew 8% to $6.57. Full year revenue grew 4% to $44.56 billion. Full year GAAP diluted earnings per share (EPS) grew 7% to $17.74. Full year adjusted EPS grew 5% to $22.87. Delivered another year of excellent operational performance and share gain reflecting our active management of the company, the

    1/29/26 6:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    CVS Health to hold fourth quarter and full year 2025 earnings conference call

    WOONSOCKET, R.I., Jan. 15, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Tuesday, February 10th, 2026, at 8:00 a.m. ET to discuss fourth quarter and full year 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of S

    1/15/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/9/23 11:35:13 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials